Evidence map›Paper›PMID 38308075›Full record

ReviewInfection2024

Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections.

Majid Taati Moghadam, Ali Mojtahedi, Shakiba Salamy, Razieh Shahbazi, Naghmeh Satarzadeh, Majid Delavar, Mohammad Taghi Ashoobi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Majid Taati MoghadamDepartment of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Ali MojtahediDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shakiba SalamyDepartment of Microbiology, Faculty of Pharmacy, Islamic Azad University, Tehran, Iran.
Razieh ShahbaziDepartment of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Naghmeh SatarzadehStudent Research Committee, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Majid DelavarVice President of Health and Executive Vice President, Rey Health Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Taghi AshoobiRazi Hospital, Guilan University of Medical Sciences, Rasht, Iran. Doctorashoobi@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOver the last decade, surgery rates have risen alarmingly, and surgical-site infections are expanding these concerns. In spite of advances in infection control practices, surgical infections continue to be a significant cause of death, prolonged hospitalization, and morbidity. As well as the presence of bacterial infections and their antibiotic resistance, biofilm formation is one of the challenges in the treatment of surgical wounds.

methodsThis review article was based on published studies on inpatients and laboratory animals receiving phage therapy for surgical wounds, phage therapy for tissue and bone infections treated with surgery to prevent recurrence, antibiotic-resistant wound infections treated with phage therapy, and biofilm-involved surgical wounds treated with phage therapy which were searched without date restrictions.

resultsIt has been shown in this review article that phage therapy can be used to treat surgical-site infections in patients and animals, eliminate biofilms at the surgical site, prevent infection recurrence in wounds that have been operated on, and eradicate antibiotic-resistant infections in surgical wounds, including multi-drug resistance (MDR), extensively drug resistance (XDR), and pan-drug resistance (PDR). A cocktail of phages and antibiotics can also reduce surgical-site infections more effectively than phages alone.

conclusionIn light of these encouraging results, clinical trials and research with phages will continue in the near future to treat surgical-site infections, biofilm removal, and antibiotic-resistant wounds, all of which could be used to prescribe phages as an alternative to antibiotics.

Indexed as

Bacterial InfectionsPhage TherapySurgical WoundAnimalsAnti-Bacterial AgentsBacteriaHumansSurgical Wound InfectionAnti-Bacterial AgentsAntibiotic resistanceBiofilmsPhagesSurgerySurgical site infections

Identifiers

PMID38308075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.